XML 17 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Technology development and licensing revenue $ 500,000 $ 500,000
Operating expenses:    
Research and development 11,733,666 10,619,287
General and administrative 13,687,899 10,887,903
Total operating expenses 25,421,565 21,507,190
Loss from operations (24,921,565) (21,007,190)
Other income (expense):    
Gain from change in earn-out milestone liability 5,396,000 1,622,000
Impairment of goodwill and in-process research and development (13,366,234) (1,976,101)
Loss on debt extinguishment (234,419)
Investment income, net 453,356 10,996
Interest expense (5,028,618) (569,881)
Other income 1,801 1,899
Total other income (expense), net (12,543,695) (1,145,506)
Loss before income tax benefit (37,465,260) (22,152,696)
Income tax benefit 1,567,026 1,383,446
Net loss $ (35,898,234) $ (20,769,250)
Net loss per common share - basic and diluted $ (5.03) $ (3.83)
Weighted average common shares outstanding - basic and diluted 7,142,970 5,426,953